Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Vicadrostat and Effect of Probenecid in Healthy Subjects
NCT06647810Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 2024
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of vicadrostat in chronic kidney disease (CKD) (3 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve of BI 690517 in plasma over the time interval from 0 to the last quantifiable data point, Maximum measured concentration of BI 690517 in plasma and 1 more. Started Nov 2024; status: completed.
02
Drugs
vicadrostat
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT06647810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06647810.